Vascular Solutions LLC v. Medtronic, Inc

CourtDistrict Court, D. Minnesota
DecidedJune 27, 2025
Docket0:19-cv-01760
StatusUnknown

This text of Vascular Solutions LLC v. Medtronic, Inc (Vascular Solutions LLC v. Medtronic, Inc) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Vascular Solutions LLC v. Medtronic, Inc, (mnd 2025).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA

VASCULAR SOLUTIONS LLC; TELEFLEX No. 19-cv-1760 (LMP/SGE) LLC; TELEFLEX LIFE SCIENCES LLC; and ARROW INTERNATIONAL LLC,

Plaintiffs, ORDER ON CLAIM v. CONSTRUCTION AND SCHEDULE MEDTRONIC, INC. and MEDTRONIC VASCULAR, INC.,

Defendants.

J. Thomas Vitt, Sanjiv P. Laud, and Lucien Wang, McCurdy Laud, LLC, Minneapolis, MN; and J. Derek Vandenburgh, Tara C. Norgard, Joseph W. Winkels, and Seung Sub Kim, Carlson Caspers, Minneapolis, MN, for Plaintiffs.

Kurt J. Niederluecke, Laura L. Myers, Barbara Marchevsky, Fredrikson & Byron, P.A., Minneapolis, MN; Cara S. Donels, Fredrikson & Byron, P.A., Des Moines, IA; and Gregory Hayes Lantier, Wilmer Cutler Pickering Hale and Dorr LLP, Washington, D.C., for Defendants. Plaintiffs Vascular Solutions LLC, Teleflex LLC, Teleflex Life Sciences LLC, and Arrow International LLC (collectively “Teleflex”) brought this patent-infringement lawsuit accusing Defendants Medtronic, Inc. and Medtronic Vascular, Inc. (collectively “Medtronic”), of infringing a family of Teleflex’s patents relating to a guide-extension catheter. Currently before the Court is claim construction of the term “substantially rigid portion/segment.” For the reasons below, the Court construes “substantially rigid portion” to mean: the first proximal section of a multipart guide extension catheter that is rigid enough to allow the device to be advanced within the guide catheter. BACKGROUND On May 3, 2006, Teleflex filed U.S. Patent Application No. 11/416,629 (the ’629

application) for a coaxial guide catheter used in interventional cardiology procedures, referred to as a “guide extension catheter” (“GEC”).1 A GEC “is used by a heart surgeon to deliver an interventional cardiology device (such as a balloon or stent) into a coronary artery.” QXMédical, LLC v. Vascular Sols., LLC, No. 17‐cv‐1969 (PJS/TNL), 2018 WL 5617568 at *1 (D. Minn. Oct. 30, 2018). In 2011, the ’629 application issued as U.S. Patent No. 8,048,032 (the ’032 patent). ECF No. 575-2. Teleflex then sought and was granted

additional patents descending from the ’629 application: U.S. Patent No. 8,142,413 (the ’413 patent); U.S. Patent No. RE45,380 (the ’380 patent); U.S. Patent No. RE45,760 (the ’760 patent); U.S. Patent No. RE45,776 (the ’776 patent); U.S. Patent No. RE46,116 (the ’116 patent); and U.S. Patent No. RE47,379 (the ’379 patent) (collectively, the “Patents- in-Suit”). Vascular Sols. LLC v. Medtronic, Inc., 117 F.4th 1361, 1363 (Fed. Cir. 2024)

(hereinafter “Appellate Decision”). For the present stage of this litigation, Teleflex asserts

1 The development of the GEC, the medical procedure in which it is used, and the lengthy procedural history of this case are extensively detailed in previous orders from the Honorable Patrick J. Schiltz and the Federal Circuit Court of Appeals. See QXMédical, LLC v. Vascular Sols., LLC, No. 17‐cv‐1969 (PJS/TNL), 2018 WL 5617568 (D. Minn. Oct. 30, 2018); Vascular Sols. LLC v. Medtronic, Inc., No. 19-cv-1760 (PJS/TNL), 2022 WL 832102 (D. Minn. Mar. 21, 2022); Vascular Sols. LLC v. Medtronic, Inc., No. 19-cv- 1760 (PJS/TNL), 2022 WL 17959845 (D. Minn. Dec. 27, 2022); Vascular Sols. LLC v. Medtronic, Inc., No. 19-cv-1760 (PJS/TNL), 2024 WL 95193 (D. Minn. Jan. 9, 2024); Medtronic, Inc. v. Teleflex Innovations S.a.r.l., 70 F.4th 1331, 1333 (Fed. Cir. 2023); Vascular Sols. LLC v. Medtronic, Inc., 117 F.4th 1361, 1363 (Fed. Cir. 2024). The Court assumes familiarity with that background and will only reference that which is relevant to this order. claims 9, 13, and 18 of the ’032 patent; claim 4 of the ’413 patent; and claim 25 of the ’776 patent. ECF No. 574 at 4.

Of importance here is that Teleflex’s ’032 patent, from which all the Patents-in-Suit descend, is a GEC described as “generally” including “a tip portion, a reinforced portion, and a substantially rigid portion.”2 ’032 patent at 3:27–30. The “tip portion,” represented by segment 16, includes segments 22, 24 and 26 from Figure 4. Id. at fig. 4, 6:14–18. The reinforced portion is represented by number 18, and includes 28, 30, and 32. Id. at 6:24– 28. And, together, the tip and reinforced portion “form a substantially cylindrical

structure.” Id. at 6:29–30. The substantially rigid portion, on the other hand, “includes first full circumference portion 34, hemicylindrical portion 36, arcuate portion 38, and second full circumference portion 40,” and “may be formed from a hypotube or a section of stainless steel or Nitinol tubing,” though other materials may be used. Id. at 6:34–40. The substantially rigid portion was, in the past, colloquially referred to by all parties as the

“pushrod.” See Vascular Sols. LLC v. Medtronic, Inc., No. 19-cv-1760 (PJS/TNL), 2022 WL 832102, at *3–4 (D. Minn. Mar. 21, 2022) (hereinafter “Preliminary Injunction Order”) (recounting Teleflex’s history of equating the “substantially rigid portion” with the pushrod).

2 Although the claim at issue uses the phrase “substantially rigid portion,” the parties and previous courts have consistently used the words “segment” and “portion” interchangeably. Appellate Decision, 117 F. 4th at 1367 (noting that both Teleflex and Medtronic have equated “‘portion” or “segment’”). This Court will do the same. Fig. 4 26 et a2 = ee oe 28 30 “32 ~34 36 38

patent at fig. 4. In general terms, the product contains a long “substantially rigid portion” that eventually connects to a tube; that tube, in turn, contains a side opening on the proximal side. Indeed, though the patents do not themselves contain the term “side opening,” each patent claims a “side opening” at the proximal end of the substantially cylindrical structure. Appellate Decision, 117 F.4th at 1364 n.5 (noting that some of the patents use the phrase “partially cylindrical” to describe the side opening while others use the phrase “hemicylindrical portion”). I. Initial Claim Construction and Finding of Invalidity In April 2017, QXMédical, LLC (“QXMédical’”), which produced and sold its own GEC, brought a declaratory judgment action against Teleflex seeking a judgment that its GEC did not infringe any of Teleflex’s patents. See OXMeédical, 2018 WL 5617568, at *1. During the early stages of that litigation—which remains pending—the court was asked to define “substantially rigid” within the context of “substantially rigid portion,” and defined it as “rigid enough to allow the device to be advanced within the guide catheter.” Jd. at *5.

In 2019, Medtronic entered the GEC market. Medtronic, Inc. v. Teleflex Innovations S.a.r.l., 70 F.4th 1331, 1335 (Fed. Cir. 2023). Teleflex brought this suit soon after, alleging

that Medtronic’s GEC infringed its patents. Appellate Decision, 117 F.4th at 1366. During the present litigation, claim construction evolved from defining the phrase “substantially rigid,” to defining the phrase “substantially rigid portion.” Id. at 1367 (emphasis added). This has, ultimately, led to the lengthy litigation in this case because while “substantially rigid” proved simple enough to define, defining the “portion” of a device that was “substantially rigid” has proven more difficult.

The issue is that—although every patent secured by Teleflex includes a substantially rigid portion—the claimed substantially rigid portion has evolved through Teleflex’s seven patent applications. Specifically, the patents differ as to how the substantially rigid portion interacts with other aspects of the device, particularly the side opening. Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Vascular Solutions LLC v. Medtronic, Inc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/vascular-solutions-llc-v-medtronic-inc-mnd-2025.